High blood pressure, also called hypertension, is a chronic condition in which arterial pressure remains elevated over time. It often has no symptoms but significantly increases risk of heart attack, stroke, kidney disease, and other cardiovascular complications. Long-term management includes lifestyle changes and antihypertensive medications.
Research and survey data point to lifelong learning, midlife stimulating activities and treatment of health risks as factors linked to better brain health and lower dementia risk.
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
People with blood type B have a 28% higher risk of type 2 diabetes, while artificial sweetener consumption is linked to faster cognitive decline, particularly in younger adults and those with diabetes. The blood type finding comes from an umbrella review of 51 systematic reviews, while the sweetener study followed 12,772 Brazilian adults for eight years.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
GLP-1 receptor agonists like semaglutide and tirzepatide help regulate appetite and improve satiety for medical weight loss. Clinical studies show patients can lose an average of 15% of body weight with these treatments. These medications are suitable for individuals with BMI of 27+ with weight-related conditions or BMI of 30+ regardless of other conditions.
Zealand Pharma's petrelintide achieved up to 10.7% average weight loss after 42 weeks in a 493-patient phase 2 trial, with placebo-like tolerability but lower efficacy than competing amylin drugs, causing Zealand shares to drop 34%.
A clinical trial shows baduanjin, a traditional Chinese mind-body practice, reduces blood pressure by 3-5 points, comparable to first-line medications and brisk walking, with effects sustained for one year.
The Preeclampsia Foundation released a new educational resource to help OB-GYNs navigate predictive and diagnostic biomarker testing for hypertensive disorders of pregnancy, covering FDA-cleared tests from Thermo Fisher Scientific and Roche Diagnostics.
The FDA approved an oral version of Wegovy in December 2025, providing a pill alternative to injections. Clinical trials showed comparable effectiveness between oral and injectable forms of semaglutide for weight loss.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602166 |
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans |
NOT_YET_RECRUITING | PHASE2 |
| NCT07582523 |
Out-of-office Monitoring for Rhythms Of Normal Versus Atrial Fibrillation |
ENROLLING_BY_INVITATION | NA |
| NCT07506707 |
Digital Education for Hypertension Management: Effects on Self-Care and Health Literacy |
NOT_YET_RECRUITING | NA |
| NCT07459348 |
Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Chronic HD Patients? |
NOT_YET_RECRUITING | NA |
| NCT07420465 |
Cardiometabolic Risk in Pregnancy and Postpartum |
NOT_YET_RECRUITING | NA |
| NCT07398391 |
Blood Pressure Care for Advancing Real-World Evidence (BPCARE) |
RECRUITING | NA |
| NCT07386535 |
Innovative Tools to Expand Music-Inspired Strategies for Blood Pressure and Stroke Prevention |
RECRUITING | NA |
| NCT07383220 |
Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure |
RECRUITING | NA |
| NCT07330804 |
STUDY OF THE DOUBLE POLYMORPHISM (THR 555ILE) AND (GLU568PRO) OF THE CORIN GENE AS A RISK FACTOR FOR ARTERIAL HYPERTENSION IN A POPULATION OF AFRICAN DESCENT IN GUADELOUPE |
RECRUITING | NA |
| NCT07267871 |
Oura Blood Pressure Profile Study |
RECRUITING |
